February 2024

Maximizing Liquid Biopsy Sensitivity through the Power of DNA-Binding Antibodies

2024-02-13T11:12:59-05:00February 1st, 2024|Webinars|

March 7, 2024 @ 11am EST In this webinar, you will learn: Non-Invasive Liquid Biopsies: Cell-free DNA as a key analyte for non-invasive liquid biopsies for cancer diagnosis and monitoring. Enhanced Cell-Free DNA Recovery: Strategies to improve cell-free DNA recovery, including the use of DNA priming agents like DNA-binding monoclonal antibodies. [...]

January 2024

October 2023

New Antibody Characterization Essentials from Discovery to Clinic

2023-10-27T10:34:59-04:00October 4th, 2023|Webinars|

In this webinar, you will learn: Workflows for antibody characterization that extend beyond the primary amino acid sequence How to leverage HDX-MS for epitope mapping and SPR for binding kinetics to understand the mechanism of action and maximize the effectiveness of your characterization efforts How to ensure high-quality antibody production with [...]

September 2023

Antibody Developability: Sequence and Structure Impacts Antibody Aggregation

2023-09-12T16:43:59-04:00September 12th, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: September 12, 2023 Contents Introduction Mechanisms That Influence Protein Aggregation and Stability Sequence and Structural Characteristics That Impact Antibody Aggregation and Stability Engineered Antibody Formats Influence Protein Aggregation Strategies to Reduce Antibody Aggregation Propensity Improving Antibody Developability with Next Generation Protein Sequencing and Proteomics [...]

August 2023

Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More

2023-11-09T13:19:41-05:00August 29th, 2023|Webinars|

In this webinar, you will learn: Antibody technologies for the design of unique antibody formats Advancements in engineering efforts for the development of functionally tailored antibodies, recombinant isotype antibody panels, and multivalent fragment antibody constructs Characterization of different bispecific antibody formats Next generation protein sequencing to aid in bispecific antibody design [...]

July 2023

Antibody Discovery Dead Ends and New Approaches

2023-08-24T15:35:59-04:00July 20th, 2023|Webinars|

In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]

Primary and Secondary Antibodies in Immunoassays

2023-07-07T10:10:31-04:00July 7th, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: June 13, 2023 Contents Introduction How do Primary and Secondary Antibodies Work? How are Primary and Secondary Antibodies Generated? Selecting Primary and Secondary Antibodies for Immunoassays Developing Reliable Reagents for Immunoassays with Rapid Novor Introduction Immunoassays have a [...]

June 2023

CAR-iNKT Cells Targeting Clonal TCRVβ Chains as a Precise Strategy to Treat T Cell Lymphoma

2023-11-09T13:27:52-05:00June 16th, 2023|Case Studies|

With 22 functional T cell receptor (TCR)Vβ subunit families making up the normal T cell repertoire, signals from these cell surface receptors often determine the fate of normal cells. However, mutations in TCR signaling proteins are frequently associated with peripheral T cell lymphomas (TCLs), including adult T cell leukemia/lymphoma (ATL), which indicates a driving role for TCRs in TCL oncogenesis. As TCL and ATL are clonal in nature, tumour cells typically express a single TCRVβ subunit with no bias in the usage of TCRVβ subunit families. Consequently, targeting the specific TCRVβ subunit presents a promising therapeutic approach that is highly selective and tumour-specific.

Antibody Drug Discovery and Development

2023-06-09T11:40:17-04:00June 9th, 2023|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: June 6, 2023 Contents The Drug Development Pathway: Overview and Challenges Early Discovery and Development of Therapeutic Antibodies Target Identification and Validation Antibody Discovery and Expression Lead Characterization and Selection Lead Engineering and Optimization Candidate Selection The Drug Development Pathway: Overview [...]

Tackling Reproducibility in Life Sciences with Next Generation Protein Sequencing and Recombinant Expression

2023-06-21T10:24:06-04:00June 2nd, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: May 9, 2023 Contents Introduction Hybridoma Instability Leads to mAb Irreproducibility Batch-to-Batch Variation in Polyclonal Antibodies Antibody Sequencing and Recombinant Expression Ensures Reproducible Antibody Reagents Generating Reproducible Reagents with Rapid Novor Introduction Antibodies (Abs) are indispensable tools in [...]

May 2023

Rational Antibody Design and Engineering with Next Generation Protein Sequencing

2023-11-09T13:21:24-05:00May 9th, 2023|Webinars|

In this webinar, you will learn: A strategy for generating recombinant mAbs and antibody derivatives directed towards antigens involved in mitotic cell division Methods for antibody engineering and customization, species switching, and construction of antibody fragments How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid engineering and recombinant production of [...]

Functional Characterization of Therapeutic Antibodies

2023-05-15T11:02:52-04:00May 3rd, 2023|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: April 24, 2023 Contents Introduction Functions of Therapeutic Antibodies Functional Assays for Therapeutic Antibodies Functional Characterization in the Therapeutic Antibody Discovery Process Introduction Monoclonal antibodies (mAbs) and related biological products often present as ideal therapeutics largely due to: Their [...]

April 2023

The Shortcut to Reliable Diagnostic, Control, and Assay Antibodies

2023-06-21T10:15:28-04:00April 5th, 2023|Webinars|

In this webinar, you will learn: IVD and immunoassays, supply chain risk management considerations How monoclonal and polyclonal antibody sequencing works, requirements Effective production, validation, and scale-up of recombinant antibody reagents Characterization of mAbs for assay design Abstract Polyclonal antibodies (pAbs) are well known for their robustness and [...]

Navigating Intellectual Property Protection for Antibodies

2023-06-21T10:21:38-04:00April 1st, 2023|Webinars|

In This Webinar, You Will Learn: Why IP is important in the development of antibody-based assets Patent application process and requirements How to strengthen patent applications Applications of Next Generation Protein Sequencing, SPR, and HDX-MS for antibody-related patent applications Abstract In the development of novel and innovative antibody-based [...]

February 2023

Towards Antigen-Specific Tregs for Type 1 Diabetes: Construction and Functional Assessment of Pancreatic Endocrine Marker, HPi2-Based Chimeric Antigen Receptor

2023-06-21T11:03:11-04:00February 3rd, 2023|Case Studies|

Antibodies with established, specific targets can be sequenced and utilized to engineer the hinge region and antigen-binding domains with antibody fragments and derivatives. With the sequence information in hand, further steps to optimizing a viable therapeutic approach can be more accessible.

December 2022

The Hunt for Novel Therapeutics Through Antibody Engineering

2023-06-21T10:25:09-04:00December 2nd, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: November 1, 2022 Contents Introduction Approaches for Engineering Antibody Therapeutics Driving Antibody Engineering with Next Generation Protein Sequencing and Proteomics Introduction Antibody engineering encompasses various development, production strategies, and modification techniques to improve the biological properties of monoclonal antibodies (mAbs) [...]

October 2022

Resistance to Autosomal Dominant Alzheimer’s Disease in an APOE3 Christchurch Homozygote

2023-06-21T11:02:47-04:00October 21st, 2022|Case Studies|

De novo protein sequencing provided the research team with insurance by securing the complete amino acid sequence of a therapeutic mAb candidate for ADAD. This mass spectrometry-based protein sequencing technique can be used to obtain the sequence information of any antibody or protein for biomarker discovery, characterization, and validation. Access to this structural information only broadens our understanding of disease pathogenesis and fosters the development of innovative therapeutic or preventative treatments.

September 2022

Antibody-Drug Conjugates as Anti-Cancer Therapeutics

2024-01-22T13:13:13-05:00September 19th, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached [...]

Characterizing Fragile Protein Complexes

2023-05-15T12:45:26-04:00September 14th, 2022|Webinars|

Webinar Highlights You will learn: Introduction to the structure and function of the tuberous sclerosis protein complex (pTSC) A novel strategy for isolating and purifying protein complexes from native sources using recombinantly produced Fabs How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid design and engineering of recombinant antibody [...]

August 2022

What Generates Antibody Diversity?

2023-05-25T10:32:38-04:00August 31st, 2022|Articles|

Written by Genya Gorshtein, MSc Updated: January 27, 2023 (Published: August 31, 2022) Contents How is Antibody Diversity Generated? Which Steps Contribute to the Generation of Antibody Diversity? Antibody Loci and V(D)J Recombination Somatic Hypermutation Class Switch Recombination De Novo Proteomic Sequencing of Antibodies How is Antibody [...]

Structure and Function of Antibodies

2023-05-25T10:40:39-04:00August 10th, 2022|Articles|

Written by Genya Gorshtein, MSc August 10, 2022 Contents General Structure of Antibodies Fab and Fc Fragments Hinge Region CDR and FR Regions Antibody Structure Analysis Services General Structure of Antibodies Antibodies or immunoglobulins (Ig) maintain a common quaternary structure consisting of two identical heavy chains (HCs) and two [...]

Moving Towards Biosimilar Drugs

2023-06-22T10:38:32-04:00August 4th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: August 3, 2022 Contents What are Biosimilar Drugs? Why are Biosimilars Being Developed? Biosimilars are not the Equivalent of Generics Biosimilar Development Biosimilar Monoclonal Antibodies De Novo Protein Sequencing Solutions in Biosimilar Development What are Biosimilar Drugs? Biosimilar drugs, [...]

July 2022

Adeno-Associated Virus Vectors for Gene Therapy Delivery

2023-06-22T10:41:47-04:00July 14th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: July 11, 2022 Contents What is Gene Therapy? What are Adeno-Associated Viruses? Engineering of AAVs for Gene Therapy Engineering AAVs for Improved Transduction Engineering AAVs for Improved Immunogenicity De Novo Protein Sequencing Applications in AAV Characterization and Development What is Gene [...]

Next Generation Vaccine Development with Proteomics

2023-06-21T11:01:12-04:00July 5th, 2022|Webinars|

As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. By comparing the antibody response towards specific wild-type influenza strains and COBRA antigens, we can begin to understand the potential for COBRA-based vaccines to be used in the clinic.

June 2022

Chimeric Antigen Receptors and T cells – CAR-T

2023-06-22T10:39:28-04:00June 21st, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: June 13, 2022 Contents What is CAR-T Cell Therapy? CAR Structure and Function CAR-T Cell Development Engineering Strategies for CAR-T Cells De Novo Protein Sequencing Applications in CAR-T Cell Development What is CAR-T Cell Therapy? The infusion of T cells [...]

Characterization and Modulation of Anti-αβTCR Antibodies and Their Respective Binding Sites at the βTCR Chain to Enrich Engineered T Cells

2023-06-21T11:00:56-04:00June 17th, 2022|Case Studies|

αβTCR-engineered T cells have been applied in clinical trials, specifically directed against cancer/testis antigens. Though the clinical outcomes are promising, only a small proportion of patients benefit from these novel treatments. Lower response rates are partially attributed to a heterogeneous mixture of non-engineered and poorly engineered T cells that remain in the administered therapeutic product. For successful translation of these novel treatments into the clinic, engineering efforts should be reinforced with effective methods for engineered T cell purification and engineered T cell elimination post infusion into patients.

Why do Post-Translational Modifications Matter?

2023-05-15T11:19:45-04:00June 14th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Updated: January 19, 2023 (Published: June 2, 2022) Contents What are post-translational modifications (PTMs)? Impact of PTMs Types of PTMs PTMs increase microheterogeneity of antibodies Characterization of PTMs by next generation protein sequencing The Importance of Post-Translational Modifications (PTMs) Post-translational [...]

Protein Structure and How to Study It

2023-05-15T11:21:16-04:00June 10th, 2022|Articles|

Written by: Yuning Wang, PhD Updated: January 26, 2023 (Published: June 3, 2022) Contents Introduction The Four Levels of Protein Structure How are Protein Structures Studied? Introduction Structural information provides a great deal of understanding of how a protein works, which can allow us to [...]

May 2022

Enriching Engineered T Cells with Antibody Sequencing & Modulation

2023-06-21T10:59:48-04:00May 10th, 2022|Webinars|

Known, high-performing and well used antibodies against useful targets on CAR-T cells can be examined for mechanism of action using proteomics and mass spectrometry. Knowledge of the antibody sequences via Next Generation Protein Sequencing (NGPS) can be useful for humanizing or otherwise engineering constructs. Rapid Epitope mapping by HDX can be useful for both epitope and paratope engineering strategies.

April 2022

Broadly Neutralizing Antibody Cocktails Targeting Nipah Virus and Hendra Virus Fusion Glycoproteins

2023-06-21T10:18:26-04:00April 29th, 2022|Case Studies|

Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.

Generation and Diversification of Recombinant Monoclonal Antibodies

2023-06-21T10:54:12-04:00April 22nd, 2022|Case Studies|

Monoclonal antibodies are essential reagents and research tools. They are commonly generated and produced in hybridoma cells and are expected to be highly consistent. However, the instability and fragility of hybridoma cells can cause unwanted mutations, additional chains, and permanent loss of important antibodies. On the other hand, the lack of standardization validation for commercial antibodies often keeps researchers in the dark leading to the reproducibility crisis. 

March 2022

First Immunoassay for Measuring Isoaspartate in Human Serum Albumin

2023-06-21T10:52:50-04:00March 25th, 2022|Case Studies|

The ongoing pandemic has reinforced the need for in vitro diagnostics to globally surveille emerging pathogens and provide better medical care. In particular, immunoassays are favoured due to their affordability, ease, and speed. Nevertheless, the combination of rapidly evolving pathogens, and more complex diseases resulting from increasing life expectancy worldwide require more sensitive and specific immunoassays in the nick of time. To increase sensitivity, immunoassay development can benefit from exploiting industry-leading technologies such as de novo protein sequencing.

February 2022

Camelid Antibodies and Nanobodies

2023-05-15T11:27:38-04:00February 4th, 2022|Articles|

Written by: Yuning Wang, PhD Updated: January 18, 2023 (Published: January 21, 2022) Contents Discovery of Camelid Antibodies What are Camelid Antibodies? Structure of Camelid Antibodies and Nanobodies Advantages of Camelid Antibodies and Nanobodies Camelid Antibodies and Nanobodies for Therapeutic and Research Applications How are Camelid Antibodies [...]

January 2022

Recombinant Therapeutic pAbs are Now Possible

2023-06-21T10:58:13-04:00January 20th, 2022|Webinars|

Polyclonal antibodies are popular research reagents for their high sensitivity and robust cross-platform performance. But few companies consider them viable for therapeutic applications as they are almost impossible to characterize. Additionally, they suffer from a lack of reproducibility and limited supply. Monoclonal antibodies (mAbs) can be reliably characterized and produced for therapeutic applications, but are more costly to discover and develop. Rapid Novor’s REpAb technology can overcome these limitations by capturing the sequences of the most abundant IgG in a pAb and enabling indefinite antibody production. Here we report the first successful conversion of a goat polyclonal antibody into a cocktail of recombinant mAbs using only the pAb protein sample.

Recombinant Antibodies: A New Generation Enabled by Protein Sequencing

2023-06-21T10:52:26-04:00January 19th, 2022|Articles|

Recombinant antibodies are artificially synthesized antibodies. Recombinant antibodies are generated from expression systems (e.g., E.coli, yeast, mammalian cell lines) via transfection with two separate plasmids encoding the amino acid sequences for the light and heavy chains, respectively. In order to recombinantly produce mAbs, the amino acid sequence of the light and heavy chains must be known. There are many ways to obtain the sequence of an antibody.

December 2021

Next Generation Protein Sequencing in Veterinary Medicine and Industry

2023-05-15T12:31:25-04:00December 3rd, 2021|Whitepapers|

Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply

November 2021

October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2023-05-15T12:31:01-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

Structure of an Amino Acid

2023-05-15T11:35:12-04:00September 14th, 2021|Articles|

Amino acids are small organic molecules that make up peptides and proteins. All living organisms share the same set of amino acids. Amino acids come together in different orders (sequences) to form proteins. As such, each type of protein has a different three-dimensional structure and biological activity.

Why is Protein Sequencing Useful?

2023-05-15T11:37:24-04:00September 3rd, 2021|Articles|

Protein sequencing is a method that typically utilizes mass spectrometry (MS) to determine the amino acid code of a protein1. Prior to the development of mass spectrometry, Edman degradation, a method involving the stepwise degradation of peptides to derive the order of amino acids, was the mainstream approach. Nowadays, mass spectrometry is favored due to its ease of use and high throughput capabilities, though Edman degradation is still employed for specific applications in which the technique is well suited.

August 2021

What are Monoclonal Antibodies?

2023-05-15T11:39:30-04:00August 25th, 2021|Articles|

Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases

How to Determine Peptide Sequences

2023-05-15T11:41:09-04:00August 17th, 2021|Articles|

Amino acids (aa)—the building blocks of proteins—are simple molecules characterized by a variable R group flanked either side by an amino group and a carboxyl group. With around 20 different commonly found amino acids, each one can bond with another to produce chains that can be classified as peptides (typically below 50 aa) and proteins (sequences above 50 aa)—molecules ubiquitous to every known organism.

Key Pain Points in Amino Acid Sequencing & How to Avoid Them

2023-05-15T11:42:16-04:00August 13th, 2021|Articles|

Amino acid sequencing is commonly performed using Edman degradation or mass spectrometry (MS). While mass spectrometry is favoured for its high throughput capabilities and ease of use, both techniques possess their own features and limitations. This article summarizes some of the key pain points inherent in the two methodologies when determining the amino acid sequence.

De Novo Protein Sequencing vs DNA Sequencing

2023-06-21T10:46:57-04:00August 1st, 2021|Articles|

DNA sequencing is the process of determining the precise order of four nucleotides bases—adenine (A), guanine (G), cytosine (C), and thymine (T)—that make up the DNA molecule. From Sanger sequencing to next-generation sequencing (NGS), DNA sequencing’s accessibility and ease of use make it one of the most widely used technologies in life sciences.

July 2021

Why Verifying the Protein Sequence Is Crucial for Antibody Validation

2023-06-21T10:46:18-04:00July 23rd, 2021|Articles|

As proteins are assembled, they fold into different structural orders: from primary to quaternary. The exact sequence of the primary structure (the amino acid sequence) will dictate how a protein will fold and function. The importance of the primary structure has been noted in several studies, where changes in the original amino acid sequence have resulted in affinity problems, binding disruption, reduced half-life, and higher aggregation odds.

Fully Harnessing the Power of Immunotherapy through Protein Sequencing

2023-06-21T10:58:53-04:00July 20th, 2021|Webinars|

Of interest to human and veterinary drug development scientists, biologics and biosimilars development scientists, scientists performing pre-clinical assay development, immunotherapy researchers, oncolytic therapy development scientists, gene therapy development scientists, gene therapy, and oncolytic therapy researchers, CAR-T, and CAR-NK development scientists

What is the De Novo Amino Acid Sequencing Method?

2023-06-21T10:45:26-04:00July 19th, 2021|Articles|

Proteins are composed of peptide chains, which in turn are made up of a string or linear sequence of amino acids. Every amino acid has a basic structure containing an amino (-NH2) group and a carboxylic (-COOH) group (Figure 1B). To form a peptide, amino acids link to each other via a peptide bond, which involves the reaction between the carboxylic group of one amino acid and the amine group of another amino acid.

What is Protein Mass Spectrometry?

2023-06-21T10:44:34-04:00July 18th, 2021|Articles|

Protein mass spectrometry refers to the use of mass spectrometry in studying and characterizing proteins, including their quantification, profiling, interaction mapping, and identification of their post-translational modifications. Protein mass spectrometry may also be referred to as mass spectrometry-based proteomics. Mass spectrometry-based proteomics comprises three approaches: top-down, middle-down, and bottom-up proteomics.

How Do You Obtain the Sequence of an Antibody?

2023-05-15T11:49:55-04:00July 10th, 2021|Articles|

Antibody sequences are critical for antibody engineering and protein characterization in therapeutic development. For antibody reagent users, knowing the sequences allows them to perform sequence analysis/alignment to identify binding and cross-reactivity so they can conduct rational experiment design.

Isoleucine and Leucine

2023-05-15T11:51:04-04:00July 7th, 2021|Articles|

Because they share the same mass, isoleucine and leucine are known as isobaric amino acids. Conventional mass spectrometry-based proteomics cannot be easily used to distinguish between isoleucine and leucine.

What is Amino Acid Sequencing?

2023-05-15T11:52:07-04:00July 5th, 2021|Articles|

Amino acid sequencing is the process of identifying the arrangement of amino acids in proteins and peptides. Numerous distinct amino acids have been discovered in nature but all proteins in the human body are comprised of just twenty different types.

June 2021

Bispecific Therapeutics Explained

2023-05-15T11:55:16-04:00June 28th, 2021|Articles|

Bispecific therapeutics are monoclonal antibodies that carry a specific antigen-binding capability on each arm. Bispecifics are thus capable of having two specificities that can either double the binding affinity of the antibody toward the same antigen (increased avidity), or can now bind to two targets. Bispecifics are most often described as two types: trispecifics and bispecific T-cell engaged antibodies (BiTE).

Major Antibody Databases and Their Applications

2023-05-15T11:56:11-04:00June 18th, 2021|Articles|

Written by María Gerpe, PhD June 18, 2021 Introduction Research publications represent an additional source of validation proof for commercially available antibodies. As such, academic and industry scientists often also rely on publication references to decide which commercial antibody to purchase. Several independent efforts exist to compile such information. For instance, [...]

April 2021

Non-Fungible Antibodies

2023-06-21T10:57:53-04:00April 20th, 2021|Webinars|

Other than a paucity in widespread use, such efforts still do not address the main issue: the uniqueness of antibodies. Unlike currency, antibodies are non-fungible. To manufacture a replica of a specific antibody, we must first know its sequence. Sometimes, scientists may obtain the sequence through nucleotide sequencing means.

March 2021

The Underlying Cause of Medical Diagnostic Invalidation

2023-05-15T12:40:02-04:00March 23rd, 2021|Whitepapers|

In-vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.

January 2021

November 2020

October 2020

Research Insurance with De Novo Protein Sequencing

2023-06-21T10:55:38-04:00October 3rd, 2020|Webinars|

If you could have guaranteed stability, certainty, and reproducibility for your research, would you be interested? Imagine this, if you’re 2 years into your project and your freezer died along with all of your important cell lines, what would you do? This is just one of the situations covered in this webinar, along with many other solutions researchers have begun to implement to safeguard their efforts. Whether you’re looking to proceed with stability and certainty or you’re looking for an immediate solution for your current reproducibility challenges, protein sequencing may be the answer.

September 2020

Leveraging Recombinant Patient Antibodies in Therapeutic Applications

2023-06-21T10:54:56-04:00September 3rd, 2020|Webinars|

Our team has perfected the art of monoclonal antibody sequencing and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony will walk through our new polyclonal sequencing platform that uses both proteomics and genomics to sequence the most abundant antibodies found in polyclonal sera.

May 2020

Introduction to De Novo Protein Sequencing

2023-06-21T10:54:37-04:00May 21st, 2020|Webinars|

In this on-demand webinar, our scientific sales executive Jennifer, will briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein sequencing into their pipelines, and discuss how Rapid Novor is able to routinely and robustly achieve 100% accuracy and 100% coverage for both monoclonal and oligoclonal antibodies.

August 2019

April 2019

February 2017

Antibody Protein Sequence Analysis Using Mass Spectrometry

2023-05-15T11:58:18-04:00February 3rd, 2017|Articles|

One of the most important pieces of information researchers need to know during early stage antibody drug research and development is the sequence information of the antibody protein. With the advancement of mass spectrometry instrumentation and technologies, it is helpful, and sometimes critical, to conduct sequence analysis using mass spectrometry experiments.

June 2016

Moving Towards Recombinant Monoclonal Antibodies

2023-05-15T11:59:37-04:00June 30th, 2016|Articles|

Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.